TY - CHAP
T1 - Differentiation of Human Embryonic Stem Cells into Mesenchymal Stem Cells by the “Raclure” Method
AU - Olivier, Emmanuel N.
AU - Bouhassira, Eric E.
N1 - Funding Information:
The monoclonal antibodies for CD44 and SSEA-4 developed by J.T. August and J.E.K. Hildreth, and D. Solter, respectively, were obtained from the Developmental Studies Hybridoma Bank, developed under the auspices of the NICHD, and maintained by the University of Iowa, Department of Biological Sciences, Iowa City, IA 52242.
Publisher Copyright:
© 2011, Springer Science+Business Media, LLC.
PY - 2011
Y1 - 2011
N2 - Mesenchymal stem cells also called mesenchymal stromal cells (MSCs) are multipotent progenitors that can be found in many connective tissues including fat, bone, cartilage, and muscle. We report here a simple method to reproducibly differentiate human embryonic stem cells (hESCs) into MSCs that does not require the use of any feeder layers or exogenous cytokines. The cells obtained with this procedure have a normal karyotype, are morphologically similar to bone marrow MSCs, are contact-inhibited, can be grown in culture for about 20–25 passages, exhibit an immuno-phenotype similar to bone marrow MSCs (negative for CD34 and CD45, but positive for CD44, CD71, CD73, CD105, CD166, HLA ABC, and SSEA-4), and can differentiate into osteocytes and adipocytes. They are also a very useful source of autogenic feeder cells to support the growth of undifferentiated hESCs. The ability to produce MSCs from hESCs should prove useful in obtaining large amounts of genetically identical and genetically modifiable MSCs that can be subsequently used to study the biology of MSCs as well as possible therapeutic applications.
AB - Mesenchymal stem cells also called mesenchymal stromal cells (MSCs) are multipotent progenitors that can be found in many connective tissues including fat, bone, cartilage, and muscle. We report here a simple method to reproducibly differentiate human embryonic stem cells (hESCs) into MSCs that does not require the use of any feeder layers or exogenous cytokines. The cells obtained with this procedure have a normal karyotype, are morphologically similar to bone marrow MSCs, are contact-inhibited, can be grown in culture for about 20–25 passages, exhibit an immuno-phenotype similar to bone marrow MSCs (negative for CD34 and CD45, but positive for CD44, CD71, CD73, CD105, CD166, HLA ABC, and SSEA-4), and can differentiate into osteocytes and adipocytes. They are also a very useful source of autogenic feeder cells to support the growth of undifferentiated hESCs. The ability to produce MSCs from hESCs should prove useful in obtaining large amounts of genetically identical and genetically modifiable MSCs that can be subsequently used to study the biology of MSCs as well as possible therapeutic applications.
KW - Adipocytes
KW - Embryonic stem cells
KW - Mesenchymal stem cells
KW - Osteocyte
UR - http://www.scopus.com/inward/record.url?scp=79952200375&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952200375&partnerID=8YFLogxK
U2 - 10.1007/978-1-60761-962-8_13
DO - 10.1007/978-1-60761-962-8_13
M3 - Chapter
C2 - 21042994
AN - SCOPUS:79952200375
SN - 9781607619611
T3 - Methods in Molecular Biology
SP - 183
EP - 193
BT - Embryonic Stem Cell Therapy for Osteo-Degenerative Diseases
PB - Humana Press Inc.
ER -